Keywords: neurogen, refocuses, after, cutting, costs, usa-based, says
Neurogen refocuses R&D after cutting costs
Article | 25 February 2008
USA-based Neurogen says it plans to expand its GABA clinical program into anxiety and schizophrenia, initiating exploratory proof-of-concept clinical studies ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
